Disorder outline PML with low T1 signals is a dubious disease in the field of the nervous system, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardized clinical care are critical to improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching the needs of a team of nationally and internationally authoritative experts to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many formerly difficult-to-treat neurological disorders have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, according to timely adjustments to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of low T1 signals associated with PML. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.